Skip to main content
Top
Published in: Radiation Oncology 1/2007

Open Access 01-12-2007 | Research

Breast-conserving surgery with or without radiotherapy in women with ductal carcinoma in situ: a meta-analysis of randomized trials

Authors: Gustavo A Viani, Eduardo J Stefano, Sérgio L Afonso, Lígia I De Fendi, Francisco V Soares, Paola G Leon, Flavio S Guimarães

Published in: Radiation Oncology | Issue 1/2007

Login to get access

Abstract

Background

To investigate whether Radiation therapy (RT) should follow breast conserving surgery in women with ductal carcinoma in situ from breast cancer (DCIS) with objective of decreased mortality, invasive or non invasive recurrence, distant metastases and contralateral breast cancer rates. We have done a meta-analysis of these results to give a more balanced view of the total evidence and to increase statistical precision.

Methods

A meta-analysis of randomized controlled trials (RCT) was performed comparing RT treatment for DCIS of breast cancer to observation. The MEDLINE, EMBASE, CANCERLIT, Cochrane Library databases, Trial registers, bibliographic databases, and recent issues of relevant journals were searched. Relevant reports were reviewed by two reviewers independently and the references from these reports were searched for additional trials, using guidelines set by QUOROM statement criteria.

Results

The reviewers identified four large RCTs, yielding 3665 patients. Pooled results from this four randomized trials of adjuvant radiotherapy showed a significant reduction of invasive and DCIS ipsilateral breast cancer with odds ratio (OR) of 0.40 (95% CI 0.33 – 0.60, p < 0.00001) and 0.40 (95% CI 0.31 – 0.53, p < 0.00001), respectively. There was not difference in distant metastases (OR = 1.04, 95% CI 0.57–1.91, p = 0.38) and death rates (OR = 1.08, 95%CI 0.65 – 1.78, p = 0.45) between the two arms. There was more contralateral breast cancer after adjuvant RT (66/1711 = 3.85%) versus observation (49/1954 = 2.5%). The likelihood of contralateral breast cancer was 1.53-fold higher (95% CI 1.05 – 2.24, p = 0.03) in radiotherapy arms.

Conclusion

The conclusion from our meta-analysis is that the addition of radiation therapy to lumpectomy results in an approximately 60% reduction in breast cancer recurrence, no benefit for survival or distant metastases compared to excision alone. Patients with high-grade DCIS lesions and positive margins benefited most from the addition of radiation therapy. It is not yet clear which patients can be successfully treated with lumpectomy alone; until further prospective studies answer this question, radiation should be recommended after lumpectomy for all patients without contraindications.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jemal A, Murray T, Samuels A: Cancer Statistics, 2003. CA Cancer J Clin 2003, 53: 5.CrossRef Jemal A, Murray T, Samuels A: Cancer Statistics, 2003. CA Cancer J Clin 2003, 53: 5.CrossRef
2.
go back to reference Solin LJ, Fourquet A, Vicini FA: Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer 2005, 103: 1137. 10.1002/cncr.20886CrossRef Solin LJ, Fourquet A, Vicini FA: Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer 2005, 103: 1137. 10.1002/cncr.20886CrossRef
7.
go back to reference Boyages J, Delaney G, Taylor R: Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Cancer 1999, 85: 616. 10.1002/(SICI)1097-0142(19990201)85:3<616::AID-CNCR12>3.0.CO;2-7CrossRef Boyages J, Delaney G, Taylor R: Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Cancer 1999, 85: 616. 10.1002/(SICI)1097-0142(19990201)85:3<616::AID-CNCR12>3.0.CO;2-7CrossRef
8.
go back to reference Kerlikowske K, Molinaro A, Cha : Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst 2003, 95: 1692.CrossRef Kerlikowske K, Molinaro A, Cha : Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst 2003, 95: 1692.CrossRef
9.
go back to reference Winchester DJ, Menck HR, Winchester DP: National treatment trends for ductal carcinoma in situ of the breast. Arch Surg 1997, 132: 660.CrossRef Winchester DJ, Menck HR, Winchester DP: National treatment trends for ductal carcinoma in situ of the breast. Arch Surg 1997, 132: 660.CrossRef
10.
go back to reference Baxter NN, Virnig BA, Durham SB, Tuttle TM: Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst 2004, 96: 443.CrossRef Baxter NN, Virnig BA, Durham SB, Tuttle TM: Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst 2004, 96: 443.CrossRef
11.
go back to reference Fisher B, Costantino J, Redmond C: Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 1993, 328: 1581. 10.1056/NEJM199306033282201CrossRef Fisher B, Costantino J, Redmond C: Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 1993, 328: 1581. 10.1056/NEJM199306033282201CrossRef
12.
go back to reference Fisher B, Land S, Mamounas E: Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol 2001, 28: 400. 10.1016/S0093-7754(01)90133-2CrossRef Fisher B, Land S, Mamounas E: Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol 2001, 28: 400. 10.1016/S0093-7754(01)90133-2CrossRef
13.
go back to reference Julien JP, Bijker N, Fentiman IS: Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: First results of the EORTC randomized phase III trial 10853. Lancet 2000, 355: 528. 10.1016/S0140-6736(99)06341-2CrossRef Julien JP, Bijker N, Fentiman IS: Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: First results of the EORTC randomized phase III trial 10853. Lancet 2000, 355: 528. 10.1016/S0140-6736(99)06341-2CrossRef
14.
go back to reference Fisher B, Dignam J, Wolmark N: Findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998, 16: 441.CrossRef Fisher B, Dignam J, Wolmark N: Findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998, 16: 441.CrossRef
15.
go back to reference Houghton J, George WD, Cuzick J: Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 2003, 362: 95. 10.1016/S0140-6736(03)13859-7CrossRef Houghton J, George WD, Cuzick J: Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 2003, 362: 95. 10.1016/S0140-6736(03)13859-7CrossRef
16.
go back to reference Fisher B, Dignam J, Wolmark N: Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial. Lancet 1999, 353: 1993. 10.1016/S0140-6736(99)05036-9CrossRef Fisher B, Dignam J, Wolmark N: Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial. Lancet 1999, 353: 1993. 10.1016/S0140-6736(99)05036-9CrossRef
19.
go back to reference Zafrani B, Leroyer A, Fourquet A: Mammographically detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity. Semin Diagn Pathol 1994, 11: 208.PubMed Zafrani B, Leroyer A, Fourquet A: Mammographically detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity. Semin Diagn Pathol 1994, 11: 208.PubMed
20.
go back to reference Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF: Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999, 354: 1896-1900. 10.1016/S0140-6736(99)04149-5CrossRef Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF: Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999, 354: 1896-1900. 10.1016/S0140-6736(99)04149-5CrossRef
21.
go back to reference Jadad AR, Moore RA, Carroll D: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996, 17: 1-12. 10.1016/0197-2456(95)00134-4CrossRef Jadad AR, Moore RA, Carroll D: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996, 17: 1-12. 10.1016/0197-2456(95)00134-4CrossRef
22.
go back to reference Clarke M, Oxman AD, eds: Analysing and presenting results. Cochrane Reviewers Handbook, 4.1.6 [updated January 2003], Section 8. In The Cochrane Library. Oxford: Update Software; 2003. Clarke M, Oxman AD, eds: Analysing and presenting results. Cochrane Reviewers Handbook, 4.1.6 [updated January 2003], Section 8. In The Cochrane Library. Oxford: Update Software; 2003.
23.
go back to reference DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7: 177-188. 10.1016/0197-2456(86)90046-2CrossRef DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7: 177-188. 10.1016/0197-2456(86)90046-2CrossRef
24.
go back to reference Emdin SO, Granstrand B, Ringberg A: SweDCIS: radiotherapy after sector resection for ductal carcinoma in situ of the breast – results of a randomised trial in a population offered mammography screening. Acta Oncol 2006, 45: 536-43. 10.1080/02841860600681569CrossRef Emdin SO, Granstrand B, Ringberg A: SweDCIS: radiotherapy after sector resection for ductal carcinoma in situ of the breast – results of a randomised trial in a population offered mammography screening. Acta Oncol 2006, 45: 536-43. 10.1080/02841860600681569CrossRef
25.
go back to reference Solin LJ, Kurtz J, Fourquet A: Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol 1996, 14: 754.CrossRef Solin LJ, Kurtz J, Fourquet A: Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol 1996, 14: 754.CrossRef
27.
go back to reference Silverstein MJ, Poller DN, Waisman JR: Prognostic classification of breast ductal carcinoma in situ. Lancet 1995, 345: 1154. 10.1016/S0140-6736(95)90982-6CrossRef Silverstein MJ, Poller DN, Waisman JR: Prognostic classification of breast ductal carcinoma in situ. Lancet 1995, 345: 1154. 10.1016/S0140-6736(95)90982-6CrossRef
28.
go back to reference Silverstein MJ, Lagios MD, Groshen S: The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 1999, 340: 1455. 10.1056/NEJM199905133401902CrossRef Silverstein MJ, Lagios MD, Groshen S: The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 1999, 340: 1455. 10.1056/NEJM199905133401902CrossRef
29.
go back to reference Lagios MD: The Lagios experience. In Ductal Carcinoma In Situ of the Breast. Edited by: Silverstein MJ. Lippincott, Williams and Wilkins, Philadelphia; 2002:303. Lagios MD: The Lagios experience. In Ductal Carcinoma In Situ of the Breast. Edited by: Silverstein MJ. Lippincott, Williams and Wilkins, Philadelphia; 2002:303.
30.
go back to reference Silverstein MJ, Lagios MD, Martino S: Outcome after invasive local recurrence in patients with ductal carcinoma in situ of the breast. J Clin Oncol 1998, 16: 1367.CrossRef Silverstein MJ, Lagios MD, Martino S: Outcome after invasive local recurrence in patients with ductal carcinoma in situ of the breast. J Clin Oncol 1998, 16: 1367.CrossRef
31.
go back to reference Holli K, Saaristo R, Isola J: Effect of radiotherapy on the interpretation of routine follow-up mammography after conservative breast surgery: a randomized study. Br J Cancer 1998, 78: 542.CrossRef Holli K, Saaristo R, Isola J: Effect of radiotherapy on the interpretation of routine follow-up mammography after conservative breast surgery: a randomized study. Br J Cancer 1998, 78: 542.CrossRef
32.
go back to reference Ernster VL, Barclay J, Kerlikowske K: Mortality among women with ductal carcinoma in situ of the breast in the population-based Surveillance, Epidemiology and End Results program. Arch Intern Med 2000, 160: 953-58. 10.1001/archinte.160.7.953CrossRef Ernster VL, Barclay J, Kerlikowske K: Mortality among women with ductal carcinoma in situ of the breast in the population-based Surveillance, Epidemiology and End Results program. Arch Intern Med 2000, 160: 953-58. 10.1001/archinte.160.7.953CrossRef
33.
go back to reference Fentimen I, Bijker N: An update on European organisation for research and treatment of cancer trial 10853 for ductal carcinoma in situ of the breast. In Ductal carcinoma in situ of the breast. 2nd edition. Edited by: Silverstein MJ. Lippincott Williams and Wilkins; 2002:447-52. Fentimen I, Bijker N: An update on European organisation for research and treatment of cancer trial 10853 for ductal carcinoma in situ of the breast. In Ductal carcinoma in situ of the breast. 2nd edition. Edited by: Silverstein MJ. Lippincott Williams and Wilkins; 2002:447-52.
34.
go back to reference Bijker N, Meijnen P, Peterse JL: Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer (EORTC) randomized phase III trial 10853. A study by EORTC Berast Cancer Coperatiove Group and EORTC Radiotherapy Group. J Clin Oncol 2006, 24: 3381-87. 10.1200/JCO.2006.06.1366CrossRef Bijker N, Meijnen P, Peterse JL: Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer (EORTC) randomized phase III trial 10853. A study by EORTC Berast Cancer Coperatiove Group and EORTC Radiotherapy Group. J Clin Oncol 2006, 24: 3381-87. 10.1200/JCO.2006.06.1366CrossRef
Metadata
Title
Breast-conserving surgery with or without radiotherapy in women with ductal carcinoma in situ: a meta-analysis of randomized trials
Authors
Gustavo A Viani
Eduardo J Stefano
Sérgio L Afonso
Lígia I De Fendi
Francisco V Soares
Paola G Leon
Flavio S Guimarães
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2007
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/1748-717X-2-28

Other articles of this Issue 1/2007

Radiation Oncology 1/2007 Go to the issue